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ABSTRACT 
 
Transforming growth factor beta 1 (TGF-β1) is one of the most studied cytokines involved in renal 
tubulo¬interstitial ﬁbrosis, which is characterized by myoﬁbroblast abundance and proliferation, and high 
buildup of extracellular matrix in the tubular interstitium leading to organ failure. Endoglin (Eng) is a 180-kDa 
homodimeric transmembrane protein that regulates a great number of TGF-β1 actions in different biological 
processes, includ¬ing ECM synthesis. High levels of Eng have been observed in experimental models of renal 
ﬁbrosis or in biopsies from patients with chronic kidney disease. In humans and mice, two Eng isoforms are 
generated by alternative splicing, L-Eng and S-Eng that differ in the length and composition of their 
cytoplasmic domains. We have previously described that L-Eng overexpression promotes renal ﬁbrosis after 
unilateral ureteral obstruction (UUO). However, the role of S-Eng in renal ﬁbrosis is unknown and its study 
would let us analyze the possible function of the cytoplasmic domain of Eng in this process. For this purpose, 
we have generated a mice strain that overexpresses S-Eng (S-ENG+) and we have performed an UUO in S-
ENG+ and their wild type (WT) control mice. Our results indicate that obstructed kidney of S-ENG+ mice 
shows lower levels of tubulo-interstitial ﬁbrosis, less inﬂammation and less interstitial cell proliferation than 
WT littermates. Moreover, S-ENG+ mice show less activation of Smad1 and Smad2/3 pathways. Thus, S-Eng 
overexpression reduces UUO-induced renal ﬁbrosis and some associated mechanisms. As L-Eng 
overexpression provokes renal ﬁbrosis we conclude that Eng-mediated induction of renal ﬁbrosis in this 
model is dependent on its cytoplasmic domain. 
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ABBREVIATIONS 
 
α-SMA, α-smooth muscle actin 
ALK1, activin receptor-like kinase 1 
ALK5, activin receptor-like kinase 5 
ANOVA, analysis of variance 
ECM, extracellular matrix 
Eng, endoglin 
ICAM-1, intercellular cell adhesion molecule-1 
NO, non-obstructed 
O, obstructed 
PDGF, Platelet-Derived Growth Factor 
SEM, standard error of the mean 
TGF-β1, transforming growth factor-β1 
VCAM-1, vascular cell adhesion molecule-1 
UUO, unilateral ureteral obstruction 
WT, wild type 
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1. INTRODUCTION 
Renal ﬁbrosis is a process in which kidney structure and function are progressively altered because of the 
excessive deposition of extracellular matrix (ECM) components in both glomeruli (glomerulosclerosis) and 
interstitium (tubulo-interstitial ﬁbrosis). Progressive tubule-interstitial ﬁbrosis is the ﬁnal common pathway 
for all kidney diseases, leading to chronic renal failure. The level of tubule-interstitial ﬁbrosis is directly 
related to the impairment of renal function [1]. The histopathology of tubule-interstitial ﬁbrosis is 
characterized by inﬁltration of inﬂammatory cells, tubular cell loss, ﬁbroblasts accumulation, deposition of 
interstitial matrix, and rarefaction of the peritubular microvasculature. Inﬂammatory and other renal cells 
release to the interstitium different cytokines such as Transforming Growth Factor β (TGF-β) or Platelet-
Derived Growth Factor (PDGF) that are involved in myoﬁbroblast activation and accumulation [2]. TGF-β1 is 
one of the three TGF-β isoforms (named 1-3) present in mammals. The role of TGF-β1 as key molecule in the 
development of ﬁbrosis and inﬂammation has been widely described [3–5]. TGF-β1 signaling pathway starts 
when TGF-β1 binds to its receptor type II (TβRII) which recruits the corresponding TGF-β type I receptor 
(TβRI). Two different type I receptors, named Activin receptor-Like Kinase 1 and 5 (ALK1 and ALK5 
respectively), can be recruited by TβRII. Once the heterocomplex is formed, several Smad proteins are 
phosphorylated depending of the type I receptor recruited, and then translocated into the nucleus to 
produce the corresponding cell response. Thus, ALK1 recruitment leads to Smad1/5/8 phosphorylation 
whereas ALK5 complexing promotes Smad2/3 phosphorylation [6]. 
Endoglin (Eng) is a glycosylated transmembrane protein which is mainly expressed in endothelial cells [7], 
although it is also detected in other cell types such as macrophages [8], mesangial cells [9] or ﬁbroblasts 
from ﬁbrotic tissue [10,11]. Eng is a TGF-β1 co-receptor that participates in TGF-β1 signaling, and many 
studies have addressed the involvement of Eng in several ﬁbrotic processes [11-16].Eng is overexpressed in 
kidneys of patients with chronic kidney disease [17] and in kidneys of animals with several experimental 
models of renal ﬁbrosis [15]. Alternative splicing of human and mice Eng genes generates two mRNA that 
encode for two different isoforms of the protein named L-Eng (large) and S-Eng (short), according to the 
different lengths of their cytoplasmic tails [18,19]. It has been described that L-and S-Eng differentially 
modulate the TGF-β1 signaling pathway [20,21]. A previous study from our group demonstrated that L-Eng 
over-expression increases renal ﬁbrosis after unilateral ureteral obstruction (UUO) [16]. However, the 
individual role of S-Eng in renal ﬁbrosis is still unknown. Thus, the aim of the present study was to determine 
the effect of S-Eng overexpression in renal ﬁbrosis and whether its much shorter cytoplasmic tail affects TGF-
β1 signaling in this process. For this purpose, we used a mice transgenic for S-Eng and a widely used 
experimental model of obstructive nephropathy and renal ﬁbrosis, the UUO [22].  
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Our results show that S-Eng overexpression counteracts TGF-β-induced renal ﬁbrosis. As L-Eng promotes 
renal ﬁbrosis and TGF-β-in¬duced signaling pathways during renal ﬁbrosis, we conclude that the cytoplasmic 
tail of Eng is involved in TGF-β-induced renal ﬁbrosis. 
 
2. MATERIAL AND METHODS 
2.1. Generation and characterization of S-ENG+ transgenic mice 
To generate a transgenic mice expressing human S-Eng (S-ENG+), HA-tagged L-Eng-pCAGGS [16] and S-Eng 
cDNA [18] in pCDH (System Biosciences) were used to derive the S-Eng-pCAGGS construct. The pCDH-S-Eng 
was digested with NotI and the obtained Eng fragment was inserted into the L-Eng-pCAGGS plasmid 
previously digested with NotI. The resulting S-Eng-pCAGGS vector encodes the Eng leader sequence (amino 
acids 1-25) followed by the inﬂuenza hemagglutinin epitope (HA; Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala) and 
the mature S-Eng (variant 2, amino acids 26-625). The S-Eng-pCAGGS plasmid is under the control of a 
ubiquitous actin promoter [16].The pCAGGS plasmid contains, from 5′ to 3′, a CMV enhancer, a chicken 
enhancer and promoter, a β-globin intron, an EcoRI site, and a β-globin polyadenylation motif. To obtain 
linear DNA fragments for microinjec¬tion, the expression vector S-Eng-pCAGGS was digested with SalI/KpnI 
and the Eng containing 5.0-kb fragment was separated by agarose gel electrophoresis. The puriﬁed fragment 
(Fig. 1a) was microinjected into CBAxC57BL/6J fertilized eggs at the University of Salamanca Transgenic 
Facility, using standard protocols. Progeny was screened for Eng transgene by PCR of tail DNA using forward 
(5′-AGAGCATCCTCCTCCG ACTGG-3′) and reverse (5′-TGAAGCCACGAATGTTTTTCT-3′)primers. S-ENG+ 
transgenic founders were crossed with C57BL/6J mice to perpetuate the transgenic lines. Mice were kept in 
a pathogen-free facility for genetically modiﬁed animals (Servicio de Experimentación Animal, SEA; 
University of Salamanca). 
2.2. Mice and animal disease 
All studies were performed in parallel in S-ENG+ and WT male mice aged 8 weeks. UUO procedure was 
performed as previously described [12,23]. In brief, mice were anesthetized with Isoﬂurane (Schering-
Plough, Madrid, Spain), the abdomen was opened and the left ureter was located and occluded in two places 
with 5-0 silk. The abdomen was closed with running suture and the skin was closed with interrupted sutures. 
After surgery, animals were kept warm during 3 h and a single dose of analgesic (Buprenorphine, Schering-
Plough, Madrid, Spain) was injected subcutaneously to reduce pain in the post-surgery phase. Sham-
operated (SO) animals were included as controls. Subsequently, mice were housed in a temperature-
controlled room with a 12 h light/dark cycle and fed on standard chow (Panlab, Barcelona, Spain) and water 
ad libitum. UUO was maintained during 15 days. All the studies were approved by the Animal Care and Use 
Committees of the University of Salamanca and mice were cared in compliance with the rules of European 
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Union and with the US Department of Health and Human Services Guide for the Care and Use of Laboratory 
Animals.  
2.3. Blood pressure measurement 
Blood pressure was recorded in conscious mice with an automated multichannel system by using the tail-
cuff method and a photoelectric sensor (Niprem 546; Cibertec, Madrid, Spain). Animals were previously 
accustomed for several days and measures were collected at the same hour during at least 3 days.  
2.4. Renal function measurement 
Before UUO, mice were placed in metabolic cages and urine was collected in 24 h periods. Plasma and urine 
creatinine (CrP and CrU, respectively) were measured using a commercial kit (Quantichrom™, BioAssay 
Systems). The assay was carried out according to manufacturer's instructions. Creatinine clearance (ClCr) 
was calculated: CrU × 24-h urine output × CrP-1. Urine protein concentration was measured using the 
Bradford method. 
2.5. ELISA  
Plasma concentrations of human soluble endoglin (Sol-Eng) were determined by using the Quantikine® ELISA 
kit for Human Endoglin/ CD105 (R&D Systems).  
2.6. Histology  
Histological studies were performed in 4 S-ENG+ and 4 WT animals subjected to UUO, and 4 S-ENG+ and 4 
WT animals subjected to sham-operation. Fifteen days after UUO or sham-operation, animals were 
anesthetized with Pentobarbital and perfused with heparinized saline solution. In each animal, both kidneys 
were removed, halved longitudinally and ﬁxed in 4% buffered formalin for 24 h. Subsequently, kidneys were 
dehydrated in ascending series of ethanol, cleared in xylene and embedded in parafﬁn. Kidney sections (3 
μm) were stained either for haematoxylin-eosin or Masson's trichrome for light microscopy analysis.  
2.7. Morphometric studies  
Additional 5 μm thick renal sections were cut mounted on glass slides and stained with Sirius red (Direct Red 
80, Sigma-Aldrich Quimica, Madrid, Spain) to evaluate the area occupied by collagen ﬁbres. From each 
kidney, a total of 15 interstitial images of each slide were captured and processed with a high-resolution 
video camera (Sony, DF-W-X710) connected to a light microscope (Nikon Eclipse 50i) using the 20× objective 
and a green optical ﬁlter (IF 550). The area occupied by collagen was measured using a computerized image 
analy¬sis system (Fibrosis HRR, Master Diagnóstica) as previously described [24]. The values obtained were 
expressed in square micrometers. The possible differences in tubular damage between S-ENG+ vs. WT were 
assessed in sections stained with haematoxylin/eosin. From each preparation ﬁve widely separated images 
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were digitalized and the total area of the tubular lumen was analyzed by using an image analysis system and 
a speciﬁc software [25].  
2.8. Immunohistochemical studies  
3 μm sections were processed for immunohistochemistry as follows. Sections were deparafﬁned in xylene 
and rehydrated in graded ethanol. Endogenous peroxidase was blocked with 3% hydrogen peroxide, 
followed by primary antibody incubation. Primary antibodies are speciﬁed in Table 1. Then, sections were 
washed three times in PBS and incubated with the Novolink Polymer Detection System (Novocastra, MA, 
USA), followed by reaction with 3,3′-diaminobenzidine as chromogen. Negative WT slides were prepared 
without primary antibody, as negative controls for antibody speciﬁcity. Ten images per slide were digitalized 
and processed with the same video camera and microscope described for the analysis of ﬁbrosis. The 
number of positive cells was quantiﬁed by using ImageJ software (Rasband, W.S., ImageJ, National Institutes 
of Health, Bethesda, Maryland, USA).  
2.9. Rarefaction study 
Quantiﬁcation of peritubular capillaries (PTC) loss was performed by calculating the rarefaction index as 
previously described [26]. Brieﬂy, the CD31-immunostained sections were examined across a 10 × 10 grid 
under a ×40 objective. Each square within the grid that did not contain CD31-positive capillaries was 
counted. 5 ﬁelds in the cortex and outer medulla were examined on the cross-section of each kidney, and a 
mean score per section was calculated. This scoring system, thus, inversely reﬂects PTC rarefaction, whereby 
low values represent intact capillaries and higher values indicate loss of capillaries (the minimum possible 
capillary score is 0, and the maximum score is 100).  
2.10. Western blot analysis 
For Western blot, SO, NO, O kidneys were removed from wild type and S-ENG+ mice [WT: SO (n =6); NO (n 
=8); O(n = 8) and S-ENG+:SO (n = 6); NO (n =8); O(n = 8)] and immediately stored at -80 °C. Tissue protein 
extracts were prepared as previously described [16]. Total kidney protein lysates (60 μg) were fractioned by 
SDS¬PAGE, transferred onto PVDF membrane (Millipore Billerica, MA, USA) and incubated overnight at 4 °C 
with the antibodies for endoglin, ﬁbronectin, collagen I, α-SMA, PCNA, Smad1, Smad2/3, phospho-Smad1, 
phospho-Smad3, ICAM-1, VCAM-1, COX-2, GAPDH, β-actin, ALK1 and ALK5 in the conditions speciﬁed in 
Table 2. Development was performed using a chemiluminescent reagent (ECL detection reagent, Amersham 
Biosciences) and signals were recorded on X-ray ﬁlm (Fujiﬁlm), followed by densitometric analysis (Scion 
Image).  
After considering various molecules as loading controls, it was observed that UUO induced expression 
changes in all of them. Therefore, GAPDH was used to assess loading, but not quantiﬁed neither used for 
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protein expression relativization. Moreover, reblotting was necessary for Smad1 and pSmad1, and for 
pSmad2 and Smad2/3.  
2.11. PCR analysis  
For RT-PCR analysis, total RNA was isolated using Nucleospin RNAII (Macherey-Nagel), according to the 
manufacturer's instructions. Single-strand cDNA was generated from 250 ng of total RNA using iScript RT 
Supermix (Bio-Rad). Quantitative PCR was performed in triplicate. Each 20 μl reaction contained 1 μl of 
cDNA, 400 nM of each primer, and 1× iQ SybrGreen Supermix (Bio-Rad). Standard curves were run for each 
transcript to ensure exponential ampliﬁcation and to rule out non-speciﬁc ampliﬁcation. Primers used were: 
For mouse Eng: forward 5′-GACTTCAGATTGGAATACCTTGG-3′ and reverse 5′-CAGTGCCGTGTCTTTCTGTAAT-
3′. 95°C, 5 min;40 cycles of 30s, 95°C, 30 s, 59 °C and 30 s, 72 °C. Gene expression was normalized to RPS13 
expression. The reactions were run on an iQ5 Real-time PCR detection system (Bio-Rad).  
2.12. Statistical analysis  
Data are expressed as mean ± standard error of the mean (SEM). Comparison of means was performed by 
two-way analysis of variance (ANOVA). Statistical differences between groups were assessed by the 
Bonferroni test and by the Student t-test. Data were analyzed using the GraphPad Prism 6. A p value lower 
than 0.05 was considered statistically signiﬁcant.  
 
3. RESULTS 
3.1. Characterization of transgenic mice  
We generated a transgenic mice expressing human S-Eng (S-ENG+) under the control of a ubiquitous actin 
promoter (Fig. 1a). A breeding colony of adult S-ENG+ animals has been maintained in our facilities for N2 
years. Studies were performed in the third generation of backcrossing. The S-ENG+ transgenic mice show 
normal growth and reproductive patterns (data not shown). Expression of human S-Eng was detected in 
heart, lung, spleen, kidney and liver (Fig. 1b). We proved that human endoglin is expressed in sham-operated 
(SO), non-obstructed (NO) and obstructed (O) kidneys from S-ENG+ mice (Fig. 1c). S-ENG+ animals show 
similar arterial pressure, and renal function (assessed by creatinine clearance and proteinuria) than WT mice 
(Fig. 1d). We observed high levels of plasmatic human Sol-Eng in S-ENG+ mice, that is absent from WT mice 
(Fig. 1e).  
3.2. Renal endoglin expression after UUO  
PCR studies demonstrated that murine Eng expression was marked¬ly higher in the O kidney than in the NO 
kidney in WT mice subjected to UUO. However, mouse S-Eng expression was similar in O and NO kidneys 
(Fig. 1f). This suggests that total Eng increase in O kidneys can be attributed to an increase in L-Eng levels. 
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Renal TGF-β levels were also found higher in O than in NO kidneys and no signiﬁcant differences were 
observed between S-ENG+ and control mice (Fig. 1g).  
The amount of TGF-beta type I receptor ALK1 was higher (although the difference was not statistically 
signiﬁcant) in the O than in the NO kidneys, without differences between WT and S-ENG+ mice (Fig. 1h, 
upper panel). ALK5 showed no differences between O and NO kidneys both in WT and in S-ENG+ mice (Fig. 
1h, lower panel).  
3.3. Structural kidney alterations after UUO  
SO kidneys from S-ENG+ or WT mice exhibited morphological alterations. In contrast, O kidneys from both 
mouse strains showed typical features of hydronephrosis, including medullar compression towards cortex, 
ﬂattening of both inner medulla and papillae, tubular dilation and ﬂattened epithelium in affected tubules 
(Fig. 2a). When additional slides were stained with Masson's trichrome, a higher amount of ﬁbrous tissue in 
O compared with NO kidneys was observed. The extension of ﬁbrotic tissue was higher in WT than in S-ENG+ 
animals (Fig. 2b). Furthermore, a quantitative study of ﬁbrosis extension was performed in sections stained 
with Sirius red. Thus, computer assisted analysis showed a signiﬁcantly higher ﬁbrosis area in O kidneys from 
WT than in those from S-ENG+ animals (Fig. 2c). No manifest structural alterations or ﬁbrosis were detected 
in NO kidneys or in SO kidneys from WT or S-ENG+ (Fig. 2).  
3.4. S-Eng overexpressing mice have reduced renal collagen I and ﬁbronectin contents after UUO  
Renal levels of collagen I and ﬁbronectin, two major components of extracellular matrix, were also assessed 
by immunohistochemistry and Western blot analysis. Collagen I and ﬁbronectin contents were very low in 
NO kidneys and in SO kidneys from WT or S-ENG+ mice, whereas the expression of both proteins was higher 
in O kidneys from WT than in those from S-ENG+ mice (Fig. 3a). In agreement with the 
immunohisto¬chemistry data, we observed by Western blot analysis that the content of collagen I and 
ﬁbronectin was signiﬁcantly higher in O than in NO kidneys from WT and S-ENG+ mice. The amount of both 
proteins was signiﬁcantly lower in O kidneys from S-ENG+ animals than in O kidneys from WT animals (Fig. 
3b). These results suggest that S-Eng overexpres¬sion decreases UUO-induced ECM protein accumulation. 
3.5. S-Eng overexpressing mice reduce renal myoﬁbroblast abundance after UUO  
A typical feature of the ﬁbrotic kidney is the activation and prolifer¬ation of myoﬁbroblasts in the renal 
interstitium, being these cells a major source of ECM proteins [27,28].Myoﬁbroblast abundance in the 
kidney can be assessed by the accumulation of two markers, α-smooth muscle actin (α-SMA) and ﬁbroblast 
speciﬁc protein-1 or S100A4 [29]. Immunohistochemistry analysis for α-SMA (Fig. 4a) and S100A4 (Fig. 4b) 
revealed a higher staining of both proteins in O kidneys than in NO kidneys. Immunostaining for both α-SMA 
and S100A4 was lower in O kidneys from S-ENG+ than in those from WT mice.  
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S100A4 protein content, assessed by Western blot, was also higher in O than in NO kidneys, after UUO, and 
this content was slightly lower in O kidneys from S-ENG+ mice compared with those from WT animals (Fig. 
4c).  
3.6. Effect of S-Eng overexpression on the proliferation of renal cells after UUO  
The number of proliferating renal cells was assessed by counting nuclear immunostaining of Ki67, whose 
expression is strictly associated with the proliferative process. NO and SO kidneys presented scarce positive 
Ki67-possitive nuclei in both tubules and interstitium. O kidneys from WT animals showed a signiﬁcantly 
higher number of Ki67 stained tubular and interstitial cell nuclei than those from S-ENG+ mice (Fig. 5a). By a 
separate analysis of Ki67-possitive tubular cells and Ki67-positive interstitial cells, we show that both tubular 
and interstitial Ki67 cells are in a lower quantity in O kidneys from WT and S-ENG+ mice (Fig. 5b).  
To conﬁrm these results, we analyzed the expression of proliferation cell nuclear antigen (PCNA) by Western 
blot. PCNA expression was higher in O than in NO kidneys after UUO in WT and S-ENG+ mice. PCNA content 
was lower in O kidneys from S-ENG+ than in those from WT mice (Fig. 5c). On the other hand, tubular 
damage (evaluated by tubular lumen area) was lower in O kidneys from S¬ENG+ than in those from WT mice 
(Fig. 5d). 
3.7. S-Eng overexpression reduces inﬂammation after UUO  
Inﬂammatory cell inﬁltration is one of the key processes that contribute to the establishment of tubulo-
interstitial ﬁbrosis [1,30].To evaluate if S-Eng also modiﬁes the UUO-induced renal inﬂammation process, we 
analyzed the expression of molecule characteristics of in¬ﬂammatory cells such as CD68 (a marker of 
monocytes/macrophages), COX-2 or iNOS (expressed by inﬂammatory cells) and those involved in cell 
inﬁltration such as intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1).  
Immunostaining showed the presence of numerous CD68-positive cells in the interstitium of O kidneys from 
WT or S-ENG+ animals (Fig. 6a). However, the amount of cells stained for CD68 was clearly lower in O 
kidneys from S-ENG+ than in those from WT mice. Few or no macrophages were detected in NO and SO 
kidneys from either geno¬type (Fig. 6a). Western blot quantiﬁcation of cell adhesion molecules (CAMs) 
revealed a higher content in O kidneys than in NO or SO kidneys from mice of either genotype. The amount 
of ICAM-1 and VCAM-1 was slightly lower in O kidneys from S-ENG+ than in those from WT mice (Fig. 6b), 
although the difference did not reach statistical signiﬁcance.  
Immunohistochemistry for iNOS indicated a low number of cells stained in NO and SO kidneys, whereas a 
marked staining was observed in tubular and macrophage-like interstitial cells of O kidneys from both mice 
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genotypes. The cell staining of iNOS was clearly lower in O kidneys from S-ENG+ than in those from WT mice 
(Fig. 6a).  
Western blot analysis showed that levels of COX-2 were negligible in NO and SO kidneys from both type of 
animals, but they were very high in O kidneys. COX-2 levels in O kidneys from S-ENG+ mice were significantly 
lower than in those from WT mice (Fig. 6b). Number of peritubular capillaries and small vessels (stained with 
CD31) decreased after UUO in WT and S-ENG+ mice, suggesting vascular rarefaction in the UUO model. 
However, this increase in vascular rarefaction was lower in O kidneys from S-ENG+ mice (Fig. 6c).  
3.8. Effects of S-Eng overexpression in the TGF-β/Smad signaling pathway  
To assess the effect of S-Eng on TGF-β/Smad signaling in this model of renal ﬁbrosis, we evaluated Smad1, 
Smad2 and Smad3 phosphorylation by measuring the abundance of pSmad1, pSmad2 and pSmad3 protein 
levels by Western blot and by immunohistochemistry. 
Activation of the Smad2/3 pathway has been widely associated to ﬁbrosis in several organs [15]. 
Immunohistochemistry analysis revealed a weak nuclear expression of pSmad2/3 and pSmad1/5 in NO and 
sham animals (Figs. 7a, 8a). We also observed a higher number of nuclei positive for pSmad2/3 in O than in 
NO kidneys. The number of nuclei positive for pSmad2/3 was signiﬁcantly lower in O kidneys from S-ENG+ 
than in kidneys from WT mice (Fig. 7a). Cells positive for pSmad1/5/8 were almost not detectable in SO or 
NO kidneys in both mice genotypes, whereas strong staining in many nuclei and, to a lesser extent, in 
cytoplasm was observed in O kidneys. The number of cells positive for pSmad1/5 in O kidneys from S-ENG+ 
was much lower than that observed in O kidneys from WT (Fig. 8a). 
Similar results were obtained measuring the abundance of pSmads by Western blot. pSmad 2 and 3 
abundance was much higher in O than in NO kidneys, and their abundance was signiﬁcantly lower in O 
kidneys from S-ENG+ than in O kidneys from WT mice. Total amount of Smad2/3 was similar in O and NO 
groups from both genotypes of mice (Fig. 7b). The levels of pSmad1, assessed by Western blot analysis, were 
also higher in O than in NO kidneys, being lower (although not signiﬁcant) in the O kidneys from S-ENG+ than 
in O kidneys from WT mice (Fig. 8b). Surprisingly, total Smad1 levels were also lower in O than in NO kidneys 
in both S-ENG+ and WT mice (Fig. 8b). 
 
4. DISCUSION 
Eng is expressed in many proﬁbrogenic cells as mesangial cells and renal ﬁbroblasts of the kidney, as well as 
in skin, intestinal and cardiac ﬁbroblasts, and in cultured portal ﬁbroblasts and hepatic stellate cells of the 
liver [14,31]. Eng upregulation has been observed in several experimental models of renal ﬁbrosis [12,32]. In 
agreement with these reports, our present data in the UUO model of tubulo-interstitial ﬁbrosis shows the 
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increase in both Eng mRNA and protein expression in the O kidney (Fig. 1). Several authors demonstrated 
that Eng promotes ﬁbrosis in different kidney experimental models [15,16,33-37] and other experimental 
models of tissue ﬁbrosis in organs such as heart [13,38], liver [39] or skin [40]. Two different Eng isoforms 
that differ exclusively in the intracellular tail have been reported in both humans [18] and mice [19]. 
Recently, our laboratory described that overexpression of L-Eng, the predominant isoform, promotes renal 
ﬁbrosis in the UUO model, via increasing Smad1 and Smad3 phosphorylation [16].However, the possible role 
of S-Eng in renal ﬁbrosis has not been assessed. Hence, our aim was to elucidate the possible function of this 
isoform in the ﬁbrogenic process of the kidney subjected to UUO. 
Our results demonstrate for the ﬁrst time that overexpression of the short isoform of Eng is associated to a 
signiﬁcant reduction of ECM protein synthesis and accumulation in the obstructed kidney following UUO. 
Reduced levels of α-SMA and S100A4 in these kidneys suggest that the overexpression of S-Eng leads to a 
reduced abundance of myoﬁbroblasts. On the other hand, myoﬁbroblast and tubular epithelial cell 
proliferation is a common feature of UUO model [41].In this study we have detected that Ki67 and PCNA 
expression was higher in the O than in the NO kidneys in both WT and S-ENG+ mice, but this expres¬sion 
was lower in the O kidneys of S-ENG+ than in those from WT mice. Proliferation and differentiation of 
resident ﬁbroblast are currently considered as the main sources of myoﬁbroblasts in the renal interstitium 
during ﬁbrosis [42,43]. The amount of Ki67 positive interstitial nuclei, most probably corresponding to 
myoﬁbroblasts, was lower in S-ENG+ than in WT mice. Our data suggest that S-Eng overexpression 
counteracts myoﬁbroblast proliferation and abundance after UUO. 
Vascular rarefaction and consequent tissular hypoxia is one of the main features of renal ﬁbrosis [44]. Our 
data also suggest that overexpression of S-ENG+ leads to a lower vascular rarefaction after UUO.  
We have also observed in the O kidneys of S-ENG+, compared with those from WT mice, a lower amount of 
cells expressing CD68 (a marker of monocytes/macrophages), COX-2 (an enzyme characteristic of 
inﬂammatory cells), as well as a reduced iNOS protein amount. It should be noted that blood monocytes can 
migrate to sites of inﬂammation, differentiate into macrophages and induce inﬂammatory response lead¬ing 
to tubulointerstitial injury in renal inﬂammation in the UUO model of renal ﬁbrosis [45]. Adhesion molecules 
such as ICAM-1 and VCAM-1 play a major role in monocyte macrophage inﬁltration into the kidneys [45]. The 
expression of these adhesion molecules was lower in the obstructed kidney of S-ENG+ compared with that 
from WT mice, although the difference was not signiﬁcant. The involvement of Eng in inﬂammatory cell 
inﬁltration in experimental models of kidney damage has been already demonstrated [33,37]. Thus, all our 
data suggest a lower inﬂammatory status in the O kidneys from S-ENG+ mice compared with the O kidneys 
from WT mice, a fact that could contribute to the reduction in renal ﬁbrosis observed in these animals. 
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TGF-β can exert its proﬁbrotic effect through ALK5-Smad3 pathway activation [46,47], and phosphorylated 
Smad2 and Smad3 levels are increased after UUO [48-50]. In this study, we report a markedly lower Smad2 
and Smad3 phosphorylation in O kidneys from S-ENG+ compared with those from WT mice, thus suggesting 
that the lower accumulation of ECM proteins, and hence, lower renal ﬁbrosis observed in S-ENG+ mice, 
could be based in a lower activation of this signaling pathway in the presence of S-Eng.  
On the other hand, Smad1 phosphorylation has been related with reversion of renal ﬁbrosis, when it is 
activated by other cytokines such as bone morphogenic protein-7 (BMP-7) [51,52]. However, Smad1 
phosphorylation also has been related to the ﬁbrotic process in several organs such as skin [53], liver [54] 
and kidney [55]. It has been already described that renal levels of phospho-Smad1/5/8 increase after UUO 
[50]. In the present study, we demonstrate that the levels of Smad1 phosphorylation after UUO are lower in 
S-ENG+ than in WT mice, which suggest a role for the ALK1/Smad1 pathway in the generation of renal 
ﬁbrosis in the kidney, as previously suggested [56].  
We have also observed high levels of human Sol-Eng in serum from S-ENG+ mice, whereas human Sol-Eng 
was undetectable in plasma from WT animals. Sol-Eng is produced by proteolytic cleavage of the membrane 
isoform, releasing to the plasma almost all the extracellular part of the molecule. It can be suggested that 
increased plasma levels of Sol-Eng in S-ENG+ mice derive from the cleavage of the high levels of membrane 
human S-Eng. It is thought that Sol-Eng interacts with TGF-β molecules and thus prevents its interaction with 
the cell-surface endoglin [57–59]. However, this interaction has not been demonstrated clearly. It has been 
reported that Sol-Eng cannot directly scavenge TGF-β unless a complex of Sol-Eng-sTβRII is present [60,61] 
and that the ability of a recombinant Sol-Eng to block TGF-β1 and thus block its binding to cell surface 
receptors was very low compared with soluble TβRII [62]. Consequently, our hypothesis is that the high 
levels of Sol-Eng present in the serum of S-ENG+ mice do not interfere with the TGF-β pathway and the 
reduced ﬁbrosis and inﬂammation after ureteral ligation observed in S-ENG+ mice are not due to the 
scavenging of TGF-β by Sol-Eng. However, one cannot rule out the possibility that Sol-Eng is present in 
circulation in a complex with soluble TβRII and even soluble TβRI that could scavenge TGF-β1 and blocked 
their effects on the renal cells.  
As a conclusion, whereas L-Eng overexpression has been shown to promote both Smad1 and Smad2/3 
phosphorylation, inﬂammation and renal ﬁbrosis after UUO, we now demonstrate that S-Eng overexpression 
seems to inhibit these processes. As the only difference between these Eng isoforms is the intracellular 
domain, we postulate that this intracellular region plays a major role in the effect of Eng activating Smad2/3 
and Smad1/5/8 phosphorylation, inﬂammatory cell inﬁltration and renal ﬁbrosis after UUO (Fig. 9). 
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Table 1  
 
Primary antibodies used in immunohistochemistry. 
Antigen   Supplier   Catalog number  Host   Dilution  
         species     
 
Fibronectin   Sigma-Aldrich   F3648    Rabbit  1:100  
Collagen type I   Chemicon   Ab765p   Rabbit   1:100  
   International     
α-SMA    Sigma-Aldrich   A2547    Mouse   1:1000  
S100A4   Chemicon   07-2274   Rabbit   1:100  
   International   
Ki67    Master Diagnóstica  mAD-000310QD  Rabbit   1:100  
CD68    R&D Systems   AF796    Goat   1:100  
CD31    Santa Cruz   sc-1506   Goat   1:50  
   Biotechnology     
iNOS    Santa Cruz   sc-651    Rabbit   1:50 
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Table 2  
Primary antibodies used in Western blot. 
Antigen   Supplier   Catalog number  Host   Dilution  
         species     
 
Endoglin (human)  Santa Cruz Biotech.  sc-20632   Rabbit    1:1,000  
Fibronectin   Chemicon Intern. Ab2033    Rabbit    1:1,000  
Collagen type I   Chemicon Intern. Ab765p    Rabbit    1:1000  
α-SMA    Sigma-Aldrich   A2547    Mouse    1:1,000  
S100A4    Chemicon Intern. 07-2274   Rabbit    1:1,000 
Smad1    Santa Cruz Biotech. sc-7965    Mouse    1:1,000  
Smad2/3   Cell Signaling Tech. sc-6032    Goat    1:1,000  
Phospho-Smad1   Abcam    Ab63439   Rabbit    1:1,000 
Phospho-Smad2   Calbiochem   566,415   Rabbit   1:1,000 
 Phospho-Smad3  Cell Signaling Tech. 9520   Rabbit    1:1,000  
ICAM-1    R&D Systems   AF796   Goat   1:1,000 
VCAM-1   Santa Cruz Biotech. sc-1504   Goat   1:1,000  
COX-2   Santa Cruz Biotech. sc-1745   Goat   1:1,000  
GAPDH    Ambion Appl. Biosyst. AM4300   Mouse   1:50,000 
β-actin   Sigma-Aldrich  A5441   Mouse   1:1,000  
ALK1    Abgent    AP7807a   Rabbit    1:1,000  
ALK5   Santa Cruz Biotech. sc-398    Rabbit   1:1,000 
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FIGURE LEGENDS 
Figure 1. Characterization of transgenic mice expressing human S-endoglin and analysis of endoglin 
expression after UUO. (a) Scheme of the DNA construct used to generate transgenic mice expressing human 
S-endoglin. A 5.0-kb SalI/KpnI fragment, containing a CMV enhancer, an actin enhancer/promoter, a β-globin 
(BG) intron (fragment SalI/EcoRI), the endoglin leader sequence-LS, the hemagglutinin epitope-HA, the 
human S-endoglin cDNA (fragment EcoRI/EcoRI) and a β-globin polyadenylation site-polyA (fragment 
EcoRI/KpnI), was microinjected in the pronuclei of fertilized oocytes to generate S-ENG+ mice. The 
transcription start site (TSS) and the translation initiation of the open reading frame (ORF) are indicated in 
the scheme. (b) Expression of human S-endoglin protein in different tissues (heart, spleen, lung, kidney, 
liver) from S-ENG+ mice. Protein extracts were analyzed by Western blot using anti-endoglin and anti-HA 
antibodies. As a loading control, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was included. (c) 
Expression of human S-endoglin after UUO (15 days) in WT and S-ENG+ mice. (d) Effect of human S-endoglin 
overexpression in systolic arterial blood pressure (SABP) (d1). Effect of human S-endoglin overexpression in 
renal function: creatinine clearance (d2) and proteinuria (d3) parameters. (e) Plasma concentrations of 
human soluble endoglin (Sol-Eng) in WT and S-ENG+ mice. (f) Mouse total endoglin (Left panel) and mouse 
short endoglin (Right panel) mRNA relative expression in NO and O kidneys from WT mice and S-ENG+ mice 
subjected to UUO for 15 days, analyzed by qPCR. 
Figure 2. Effect of S-endoglin overexpression on renal interstitial ﬁbrosis after unilateral ureteral obstruction. 
(a) Representative images of haematoxylin-eosin (b) Masson's trichrome staining and (c) Sirius red staining in 
sham operated (SO), non-obstructed (NO) and obstructed (O) kidneys from WT and S-ENG+ mice. In O 
kidneys we observe the main features of obstructive nephropathy: tubular dilatation (arrows) and atrophy 
(arrowhead), inﬁltration of inﬂammatory cells and hypercellularity (circles), and extracellular matrix 
deposition (stars). Bar = 100 μm. (c) Representative images and morphometric quantiﬁcation of Sirius red of 
area stained (mean ± SEM); n = 4 in each group of mice. *p b 0.05 vs. their respective SO kidneys. #p b 0.05 
vs. O kidneys from WT mice. 
Figure 3. Effect of S-endoglin overexpression on renal collagen I and ﬁbronectin after ureteral obstruction. 
(a) Representative immunohistochemistry images for ﬁbronectin and collagen I in SO, NO and O kidneys 
from WT and S-ENG+ mice. Bar = 50 μm. (b) Western blot analysis of ﬁbronectin and collagen I protein 
amount in SO, NO and O kidneys from WT and S-ENG+ mice. Densitometry analysis is represented as the 
mean ± SEM of 5–7 experiments per group. *p b 0.05 vs. SO kidneys. #p b 0.05 vs. O kidneys from WT mice. 
Figure 4. Effect of S-endoglin overexpression on myoﬁbroblast number after ureteral obstruction. (a) 
Representative immunohistochemistry images for α-SMA in SO, NO and O kidneys from WT and S-ENG+ 
mice (bar = 50 μm), and corresponding quantiﬁcation of α-SMA-positive stained area in SO, NO and O 
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kidneys from WT and S-ENG+ mice expressed in square microns. (b) Representative immunohistochemistry 
images for S100A4 in SO, NO and O kidneys from WT and S-ENG+ mice. Bar = 50 μm. (c) Western blot 
analysis of S100A4 protein amount in SO, NO and O kidneys from WT and S-ENG+ mice. Densitometry 
analysis is represented as the mean ± SEM of 5–7 experiments per group. *p b 0.05 vs. SO kidneys. #p b 0.05 
vs. O kidneys from WT mice. 
Figure 5. Effect of S-endoglin overexpression on renal cell proliferation after ureteral obstruction. (a) 
Representative immunohistochemistry images for Ki67 and quantiﬁcation of Ki67 positive cells. Bar = 50 μm. 
(b) Quantiﬁcation of total, tubular (arrows) and interstitial (arrowheads) Ki67 positive cells. (c) Western blot 
analysis of PCNA protein amount in SO, NO and O kidneys from WT and S-ENG+ mice. (d) Quantiﬁcation of 
tubular lumen area in O kidneys from WT and S-ENG+ mice. Densitometry analysis is represented as the 
mean ± SEM ofthe 5–7 experiments performed per group. *p b 0.05 vs. SO kidneys. #p b 0.05 vs. O kidneys 
from WT mice. 
Figure 6. Effect of S-endoglin overexpression on renal inﬂammation and cell adhesion proteins after ureteral 
obstruction. (a) Representative immunostaining images for CD68 (monocyte¬macrophage marker), and iNOS 
in SO, NO and O kidneys from WT and S-ENG+ mice. Bar = 20 μmin CD68 and 50 μm in iNOS images. (b) 
Western blot analysis of ICAM-1, VCAM-1 and COX-2 protein amount in SO, NO and O kidneys from WT and 
S-ENG+ mice. (c) Quantiﬁcation of peritubular capillaries and representative pictures of CD31 staining in SO, 
NO and O kidneys from WT and S-ENG+ mice. Densitometry analysis is represented as the mean ± SEM of 
the 5–7 experiments performed per group. *p b 0.05 vs. SO kidneys. #p b 0.05 vs. O kidneys from WT mice. 
Figure 7. S-endoglin overexpression on Smad2/3 phosphorylation after ureteral obstruction. (a) Phospho-
Smad2/3 representative immunostaining in SO, NO and O kidneys from WT and S¬ENG+ mice. Bar = 50 μm 
and histogram representing number of nuclei positively stained for phospho-Smad2/3 per ﬁeld in SO, NO 
and O kidneys from WT and S-ENG+ mice. Data is represented as mean ± SEM. (b) Western blot analysis of 
phospho-Smad2, phospho-Smad3 and total Smad2/3 protein levels in SO, NO and O kidneys from WT and S-
ENG+ mice. Densitometry analysis is represented as the mean ± SEM of 5–7 experiments per group (*p b 
0.05 vs. SO kidneys; #p b 0.05 vs. O kidneys from WT mice). 
Figure 8. Effect of S-endoglin overexpression on Smad1/5/8 phosphorylation after ureteral obstruction. (a) 
Phospho-Smad1/5/8 representative immunostaining for phospho-Smad1/5/8 in SO, NO and O kidneys from 
WT and S-ENG+ mice (bar = 50 μm), Bar= 50 μm and histogram representing number of phospho-
Smad1/5/8-positive nuclei per ﬁeld in SO,NO and O kidneys from WT and S-ENG+ mice. Data is represented 
as mean ± SEM. (b) Western blot analysis of phospho-Smad1 and total Smad1 protein levels in SO, NO and O 
kidneys from WT and S-ENG+ mice. Densitometry analysis is represented as the mean ± SEM of 5–7 
experiments per group. *p b 0.05 vs. SO kidneys; **p b 0.05 vs. kidneys from WT. 
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Figure 9. Schematic summary of the role of Endoglin isoforms in kidney ﬁbrosis. L-endoglin and S-endoglin 
modulate differentially TGF-β1-induced renal ﬁbrosis. L-endoglin promotes phosphorylation of Smad2/3 and 
Smad1/5/8 proteins and consequent induction of renal ﬁbrosis and inﬂammation (left hand side) whereas S-
endoglin blocks Smad2/3 and Smad1/5/8 phosphorylation and consequent induction of renal ﬁbrosis and 
inﬂammation (right hand side). This suggests that the complete cytoplasmic tail of endoglin is essential to 
regulate renal ﬁbrosis. 
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